Plasma miR-208 as a Biomarker of Myocardial Injury
Plasma miR-208 as a Biomarker of Myocardial Injury
复制标题
DOI：
10.1373/clinchem.2009.125310
复制
发表时间：
2009-11-01
影响因子：
9.3
通讯作者：
Iwai, Naoharu
中科院分区：
文献类型：
--
作者：
Ji, Xu;Takahashi, Rie;Iwai, Naoharu
背景技术背景：微小RNA（miRNA）是一种21-25个核苷酸的内源性小RNA，可以与蛋白质编码基因mRNA 3'非翻译区的位点配对，下调其表达。最近，循环miRNA已被报道为各种病理条件的有前途的生物标志物。我们评估的假设，miRNA可能会泄漏到循环血液从受伤的细胞，从而作为生物标志物识别受伤的细胞type.METHODS：我们使用异丙肾上腺素诱导的大鼠心肌损伤模型和miRNA阵列分析，以确定候选人的miRNA专门产生在心室的心脏。通过实时逆转录PCR测量个体miRNA浓度。血浆心肌肌钙蛋白I（cTnI）浓度测定与ELISA。结果：阵列分析显示，miR-208只在心脏中产生，我们选择这种miRNA作为心肌损伤的可能生物标志物。在异丙肾上腺素诱导的心肌损伤后，miR-208的血浆浓度显著升高（P < 0.0001），其时间进程与心肌损伤的经典生物标志物cTnI的浓度相似。我们的研究结果表明，分析循环miRNA可能有助于识别各种病理条件的有希望的生物标志物。(C)2009年美国临床化学协会
BACKGROUND: MicroRNAs (miRNAs) are endogenous small RNAs of 21-25 nucleotides that can pair with sites in 3' untranslated regions in mRNAs of protein-coding genes to downregulate their expression. Recently, circulating miRNAs have been reported as promising biomarkers for various pathologic conditions. We assessed the hypothesis that miRNAs may leak into the circulating blood from injured cells and thereby serve as biomarkers for identifying the injured cell type.METHODS: We used isoproterenol-induced myocardial injury in rats as a model and miRNA array analyses to identify candidate miRNAs specifically produced in the ventricles of the heart. Individual miRNA concentrations were measured by real-time reverse-transcription PCR. Plasma cardiac troponin I (cTnI) concentrations were measured with an ELISA.RESULTS: Array analyses revealed miR-208 to be produced exclusively in the heart, and we selected this miRNA as a possible biomarker of myocardial injury. Plasma concentrations of miR-208 increased significantly (P < 0.0001) after isoproterenol-induced myocardial injury and showed a similar time course to the concentration of cTnI, a classic biomarker of myocardial injury.CONCLUSIONS: The plasma concentration of miR-208 may be a useful indicator of myocardial injury. Our results suggest that profiling of circulating miRNAs may help identify promising biomarkers of various pathologic conditions. (C) 2009 American Association for Clinical Chemistry